Pipeline: Presbyopia treatment to finish Phase 3 late 2021


Orasis Pharmaceuticals drop in development for treating presbyopia

Orasis Pharmaceuticals CEO Elad Kedar says the company is looking to achieve a balance of safety, efficacy, and comfort with its drop in development for treating presbyopia. He says Phase 3 studies should finish at the end of 2021.

Related Videos
The ins and outs of fitting multifocal contact lenses with Dr Jessica Crooker
© 2023 MJH Life Sciences

All rights reserved.